AtriCure Reports Second Quarter 2016 Financial Results
-
Revenue of
$39.7 million – up 21.8% as reported, 21.5% constant currency -
U.S. sales of
$30.9 million – up 19.9% -
International sales of
$8.8 million – up 28.7% as reported, 27.4% constant currency
“We are pleased to report second quarter results which reflect many
accomplishments – we launched two new products, made progress with our
clinical trials and made strides in positioning
Second Quarter 2016 Financial Results
Revenue for the second quarter of 2016 was
Gross profit for the second quarter of 2016 was
Operating expenses for the second quarter of 2016 increased 30.9%, or
Loss from operations for the second quarter of 2016 was
Updated 2016 Financial Guidance
Management projects 2016 revenue growth of approximately 20 to 22% over full year 2015 at current exchange rates.
Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the
range of $14 to
Conference Call
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will be available through
About
Forward-Looking Statements
This press release contains “forward-looking statements”–that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. This document also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially.
Use of Non-GAAP Financial Measures
To supplement AtriCure’s condensed consolidated financial statements
prepared in accordance with accounting principles generally accepted in
ATRICURE, INC. AND SUBSIDIARIES | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(In Thousands, Except Per Share Amounts) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Domestic Revenue: | ||||||||||||||||
Open-heart ablation | $ | 14,721 | $ | 13,648 | $ | 28,689 | $ | 26,002 | ||||||||
Minimally invasive ablation | 7,990 | 5,057 | 14,715 | 9,404 | ||||||||||||
AtriClip | 7,348 | 6,286 | 14,196 | 11,789 | ||||||||||||
Total ablation and AtriClip | 30,059 | 24,991 | 57,600 | 47,195 | ||||||||||||
Valve tools | 813 | 753 | 1,544 | 1,472 | ||||||||||||
Total domestic | 30,872 | 25,744 | 59,144 | 48,667 | ||||||||||||
International Revenue: | ||||||||||||||||
Open-heart ablation | 5,438 | 4,088 | 9,910 | 8,304 | ||||||||||||
Minimally invasive ablation | 2,186 | 1,858 | 4,350 | 3,826 | ||||||||||||
AtriClip | 1,024 | 789 | 1,889 | 1,460 | ||||||||||||
Total ablation and AtriClip | 8,648 | 6,735 | 16,149 | 13,590 | ||||||||||||
Valve tools | 152 | 104 | 319 | 212 | ||||||||||||
Total international | 8,800 | 6,839 | 16,468 | 13,802 | ||||||||||||
Total revenue | 39,672 | 32,583 | 75,612 | 62,469 | ||||||||||||
Cost of revenue | 10,854 | 9,466 | 20,880 | 17,617 | ||||||||||||
Gross profit | 28,818 | 23,117 | 54,732 | 44,852 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development expenses | 9,124 | 5,862 | 17,687 | 11,471 | ||||||||||||
Selling, general and administrative expenses | 27,432 | 22,074 | 54,202 | 43,344 | ||||||||||||
Total operating expenses | 36,556 | 27,936 | 71,889 | 54,815 | ||||||||||||
Loss from operations | (7,738 | ) | (4,819 | ) | (17,157 | ) | (9,963 | ) | ||||||||
Other expense, net | (451 | ) | (64 | ) | (751 | ) | (180 | ) | ||||||||
Loss before income tax expense | (8,189 | ) | (4,883 | ) | (17,908 | ) | (10,143 | ) | ||||||||
Income tax expense | 17 | 8 | 22 | 14 | ||||||||||||
Net loss | $ | (8,206 | ) | $ | (4,891 | ) | $ | (17,930 | ) | $ | (10,157 | ) | ||||
Basic and diluted net loss per share | $ | (0.26 | ) | $ | (0.18 | ) | $ | (0.57 | ) | $ | (0.37 | ) | ||||
Weighted average shares used in computing net loss per share: | ||||||||||||||||
Basic and diluted | 31,575 | 27,304 | 31,466 | 27,187 | ||||||||||||
ATRICURE, INC. AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(In Thousands) | ||||||||
(Unaudited) | ||||||||
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash, cash equivalents, and short-term investments | $ | 42,427 | $ | 34,578 | ||||
Accounts receivable, net | 21,354 | 19,409 | ||||||
Inventories | 19,311 | 17,659 | ||||||
Other current assets | 3,373 | 3,106 | ||||||
Total current assets | 86,465 | 74,752 | ||||||
Property and equipment, net | 30,902 | 31,279 | ||||||
Long-term investments | 5,525 | 7,706 | ||||||
Goodwill and intangible assets, net | 158,210 | 159,032 | ||||||
Other noncurrent assets | 411 | 323 | ||||||
Total assets | $ | 281,513 | $ | 273,092 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 24,716 | $ | 31,138 | ||||
Other current liabilities and current maturities of capital leases | 473 | 450 | ||||||
Total current liabilities | 25,189 | 31,588 | ||||||
Capital leases | 13,504 | 13,710 | ||||||
Long-term debt | 24,969 | — | ||||||
Other noncurrent liabilities | 40,851 | 41,109 | ||||||
Total liabilities | 104,513 | 86,407 | ||||||
Stockholders' equity: | ||||||||
Common stock | 33 | 32 | ||||||
Additional paid-in capital | 361,023 | 352,900 | ||||||
Accumulated other comprehensive loss | (490 | ) | (611 | ) | ||||
Accumulated deficit | (183,566 | ) | (165,636 | ) | ||||
Total stockholders' equity | 177,000 | 186,685 | ||||||
Total liabilities and stockholders' equity | $ | 281,513 | $ | 273,092 | ||||
ATRICURE, INC. AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(In Thousands) | ||||||||
(Unaudited) | ||||||||
Six Months Ended June 30, | ||||||||
2016 | 2015 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (17,930 | ) | $ | (10,157 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Share-based compensation expense | 5,869 | 4,141 | ||||||
Depreciation and amortization of intangible assets | 4,500 | 2,693 | ||||||
Amortization of deferred financing costs | 86 | 31 | ||||||
Loss on disposal of property and equipment | 117 | 63 | ||||||
Realized (gain) loss from foreign exchange on intercompany transactions | (15 | ) | 302 | |||||
Amortization/accretion on investments | 74 | 339 | ||||||
Change in allowance for doubtful accounts | (49 | ) | 117 | |||||
Changes in operating assets and liabilities | ||||||||
Accounts receivable | (1,897 | ) | (468 | ) | ||||
Inventories | (1,595 | ) | (1,977 | ) | ||||
Other current assets | (236 | ) | (538 | ) | ||||
Accounts payable and accrued liabilities | (5,542 | ) | (1,068 | ) | ||||
Other non-current assets and liabilities | (338 | ) | 128 | |||||
Net cash used in operating activities | (16,956 | ) | (6,394 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchases of available-for-sale securities | (21,940 | ) | (10,302 | ) | ||||
Sales and maturities of available-for-sale securities | 12,404 | 20,460 | ||||||
Purchases of property and equipment | (4,341 | ) | (4,077 | ) | ||||
Increases in property under build-to-suit obligation | — | (4,806 | ) | |||||
Net cash (used in) provided by investing activities | (13,877 | ) | 1,275 | |||||
Cash flows from financing activities: | ||||||||
Proceeds from debt borrowings | 25,000 | — | ||||||
Payments on capital leases | (218 | ) | (25 | ) | ||||
Increases in build-to-suit obligation | — | 4,806 | ||||||
Payment of debt fees | (120 | ) | (62 | ) | ||||
Proceeds from stock option exercises | 2,301 | 1,854 | ||||||
Shares repurchased for payment of taxes on stock awards | (1,033 | ) | (572 | ) | ||||
Proceeds from issuance of common stock under employee stock purchase plan |
987 | 906 | ||||||
Net cash provided by financing activities | 26,917 | 6,907 | ||||||
Effect of exchange rate changes on cash and cash equivalents | 69 | (185 | ) | |||||
Net (decrease) increase in cash and cash equivalents | (3,847 | ) | 1,603 | |||||
Cash and cash equivalents - beginning of period | 23,764 | 28,384 | ||||||
Cash and cash equivalents - end of period | $ | 19,917 | $ | 29,987 | ||||
Supplemental cash flow information: | ||||||||
Cash paid for interest | $ | 577 | $ | 3 | ||||
Cash paid for income taxes | — | 20 | ||||||
Noncash investing and financing activities: | ||||||||
Accrued purchases of property and equipment | 306 | 1,652 | ||||||
Assets acquired through capital lease | 43 | 36 | ||||||
Capital lease asset early termination | 9 | — | ||||||
ATRICURE, INC. AND SUBSIDIARIES | ||||||||||||||||
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS | ||||||||||||||||
(In Thousands) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Net loss, as reported | $ | (8,206 | ) | $ | (4,891 | ) | $ | (17,930 | ) | $ | (10,157 | ) | ||||
Income tax expense | 17 | 8 | 22 | 14 | ||||||||||||
Other expense, net (a) | 451 | 64 | 751 | 180 | ||||||||||||
Depreciation and amortization expense | 2,289 | 1,382 | 4,500 | 2,693 | ||||||||||||
Share-based compensation expense | 3,027 | 2,417 | 5,869 | 4,141 | ||||||||||||
Non-GAAP adjusted loss (adjusted EBITDA) | $ | (2,422 | ) | $ | (1,020 | ) | $ | (6,788 | ) | $ | (3,129 | ) |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||
(a) Other includes: | ||||||||||||
Net interest expense (income) | $ | 417 | $ | (26) | $ | 637 | $ | (51) | ||||
Grant income | — | — | — | (35) | ||||||||
Loss due to exchange rate fluctuation | 34 | 46 | 114 | 209 | ||||||||
Non-employee stock option expense | — | 44 | — | 57 | ||||||||
Other expense, net | $ | 451 | $ | 64 | $ | 751 | $ | 180 |
View source version on businesswire.com: http://www.businesswire.com/news/home/20160804006104/en/
Source:
AtriCure, Inc.
Andy Wade
Senior Vice President and
Chief Financial Officer
513-755-4564
awade@atricure.com
or
Investor
Relations
Gilmartin Group
Lynn Pieper Lewis
415-937-5402
lynn@gilmartinir.com